|Bid||77.20 x 800|
|Ask||78.00 x 900|
|Day's Range||75.65 - 77.75|
|52 Week Range||29.85 - 80.92|
|Beta (3Y Monthly)||1.58|
|PE Ratio (TTM)||163.00|
|Earnings Date||Feb 21, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||80.00|
BioTelemetry (BEAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MALVERN, Pa., Feb. 11, 2019 -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its fourth quarter 2018 earnings on Thursday, February 21 at 4:00 PM Eastern Time. The.
Salesforce, Splunk, WWE and BioTelemetry stock are in buy zones. The top stocks boast rising earnings estimates, a rare trait in 2019.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Today we are going to look atRead More...
BioTelemetry (BEAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BioTelemetry (BEAT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
NEW YORK, Jan. 29, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Medical device company BioTelemetry Inc. has agreed to buy California-based Geneva Healthcare, a provider of remote monitoring for implantable cardiac devices, for $45 million with a promise of an additional $20 million over time. Pasadena, Calif.-based Geneva is an early stage company that has developed a cloud-based platform that aggregates data from the device manufacturer systems, enabling the company to remotely monitor all of a physician’s patients with implantable cardiac devices such as pacemakers, defibrillators and loop recorders. Geneva raised over $6 million in a private offering in 2016 and in its first full year of commercialization last year, the company reached profitability and reported $6 million of revenue. Malvern-based BioTelemetry (NASDAQ: BEAT) specializes in mobile and wireless medical technology used for remote cardiac monitoring, mobile blood glucose monitoring and centralized medical imaging.
BioTelemetry, Inc. (BEAT), the leading remote and wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, and Geneva Healthcare, Inc. (“Geneva”), the leading provider of remote monitoring for implantable cardiac devices are pleased to announce that the companies have entered into a definitive merger agreement whereby BioTelemetry will acquire Geneva. An early stage company, Geneva has developed a proprietary cloud-based platform that aggregates data from the leading device manufacturer systems, enabling the company to remotely monitor all of a physician’s patients with implantable cardiac devices such as pacemakers, defibrillators and loop recorders.
The major indexes have shown strong gains in January. Friday was no exception. Bullish breakouts emerged. The Dow Jones rose a 5th straight week.
BioTelemetry stock ranks among top stocks to watch as it carves out a new base, and this new setup could be hard to beat.
NextGen (NXGN) delivers strong growth in software, hardware and other non-recurring revenues in Q3; strong fiscal 2019 view buoys optimism.
PetMed (PETS) sees reorder sales growth in Q3. Rising competition forced the company to offer additional discounts to customers in the quarter which had a negative impact on the gross margin.